- Home
- SLQT vs MLYS Comparison
SLQT vs MLYS Comparison
Compare SLQT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- MLYS
- Stock Information
- Founded
- SLQT 1999
- MLYS 2019
- Country
- SLQT United States
- MLYS United States
- Employees
- SLQT N/A
- MLYS N/A
- Industry
- SLQT Specialty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SLQT Finance
- MLYS Health Care
- Exchange
- SLQT Nasdaq
- MLYS Nasdaq
- Market Cap
- SLQT 386.9M
- MLYS 1.0B
- IPO Year
- SLQT 2020
- MLYS 2023
- Fundamental
- Price
- SLQT $2.39
- MLYS $13.53
- Analyst Decision
- SLQT Hold
- MLYS Strong Buy
- Analyst Count
- SLQT 2
- MLYS 4
- Target Price
- SLQT $3.38
- MLYS $27.00
- AVG Volume (30 Days)
- SLQT 875.7K
- MLYS 869.4K
- Earning Date
- SLQT 05-12-2025
- MLYS 08-12-2025
- Dividend Yield
- SLQT N/A
- MLYS N/A
- EPS Growth
- SLQT N/A
- MLYS N/A
- EPS
- SLQT N/A
- MLYS N/A
- Revenue
- SLQT $1,488,701,000.00
- MLYS N/A
- Revenue This Year
- SLQT $17.72
- MLYS N/A
- Revenue Next Year
- SLQT $13.05
- MLYS N/A
- P/E Ratio
- SLQT N/A
- MLYS N/A
- Revenue Growth
- SLQT 20.41
- MLYS N/A
- 52 Week Low
- SLQT $1.62
- MLYS $8.24
- 52 Week High
- SLQT $6.86
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SLQT 52.20
- MLYS 41.08
- Support Level
- SLQT $2.25
- MLYS $13.22
- Resistance Level
- SLQT $2.53
- MLYS $14.35
- Average True Range (ATR)
- SLQT 0.10
- MLYS 0.77
- MACD
- SLQT 0.03
- MLYS -0.01
- Stochastic Oscillator
- SLQT 61.33
- MLYS 33.14
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.